Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: Comparison of results from randomised controlled and observational studies

Diabetologia

Volumn 57, Issue 7, 2014, Pages 1304-1307

  Ahrén, Bo ^a   Mathieu, Chantal ^b   Bader, Giovanni ^c   Schweizer, Anja ^c   Foley, James E ^c  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

DPP 4 inhibitor; GLP 1; Interventional; Observational; Randomised controlled trial; Sulfonylurea

Indexed keywords

GLICLAZIDE; GLIMEPIRIDE; HEMOGLOBIN A1C; METFORMIN; SULFONYLUREA; VILDAGLIPTIN; ADAMANTANE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; NITRILE; PYRROLIDINE DERIVATIVE; SULFONYLUREA DERIVATIVE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; DRUG COMBINATION; GLUCOSE BLOOD LEVEL; MIDDLE AGED; TREATMENT OUTCOME;

ADAMANTANE; ADULT; AGED; BLOOD GLUCOSE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; NITRILES; PYRROLIDINES; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 84903515239     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3222-z     Document Type: Article

References (10)

1. Bolli G, Dotta F, Rochotte E, Cohen SE (2008) Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab 10:82-90 (Pubitemid 350302434)
2. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ (2007) Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 30:890-895 (Pubitemid 46556583)
3. Matthews DR, Dejager S, Ahren B et al (2010) Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab 12:780-789
4. Ahren B, Foley JE, Bosi E (2011) Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. Diabetes Obes Metab 13:193-203
5. Schwartz D, Lellouch J (2009) Explanatory and pragmatic attitudes in therapeutical trials. J Clin Epidemiol 62:499-505
6. Treweek S, Zwarenstein M (2009) Making trials matter: pragmatic and explanatory trials and the problem of applicability. Trials 10:37
7. Mathieu C, Barnett AH, Brath H et al (2013) Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE). Int J Clin Pract 67:947-956
8. Filozof C, Gautier JF (2010) A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet Med 27:318-326
9. Bosi E, Dotta F, Jia Y, Goodman M (2009) Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab 11:506-515
10. Williams SA, Shi L, Brenneman SK, Johnson JC, Wegner JC, Fonseca V (2012) The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients. J Diabet Complicat 26:399-406